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A B S T R A C T
Purpose: The development of new drugs for the treatment of epilepsy is a major challenge for modern
neurology and its ﬁrst steps demand basic research. Preclinical studies on animal models of epilepsy are
mainly based on the analysis of brain electrical activity to detect seizures, when they are not just limited
to behavioral tests like the Racine scale.
Methods: In the present review, we discuss the importance of using time-locked video and EEG
recordings (Video-EEG) coupled with behavioral tests as tools to monitor and analyze the effects of anti-
epileptic drugs in pre-clinical research. Particularly, we focus on the utility of a multimodal approach
based on EEG/behavioral analysis to study the beneﬁcial effects of chronic rapamycin treatment as a
potential anti-epileptogenic therapy for a broad spectrum of epilepsy, including both genetic (as in
tuberous sclerosis complex) and acquired diseases.
Results: Changes and synchronization of neuronal activity of different areas have been correlated with
speciﬁc behavior in both physiological and pathological conditions. In the epileptic brain, during a
seizure there is an abnormal activation of many cells all at once, altering different networks.
Conclusion: A multimodal approach based on video, EEG analysis and behavioral tests would be the best
option in preclinical studies of epilepsy.
 2015 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
Contents lists available at ScienceDirect
Seizure
jou r nal h o mep age: w ww.els evier . co m/lo c ate /ys eiz1. Introduction
Epilepsy is one of the most important central nervous system
disorder affecting between 0.5% and 1% of the population
worldwide. Although in same cases there are different effective
options for the treatment of epilepsy (i.e. surgery or vagal nerve
stimulation), people suffering from this disorder usually require a
chronic drug treatment and nearly one third of patients with
epilepsy become medically intractable with current available drugs
[1,2]. In addition, pharmacoresistance is a major issue with about
30–40% of patients not responding to any kind of antiepileptic
drugs [3]. As a consequence, the number of untreatable patients is* Corresponding author. Tel.: +39 011-6708167.
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1059-1311/ 2015 British Epilepsy Association. Published by Elsevier Ltd. All rights refast-growing. Moreover, most current treatments are primarily
symptomatic therapies that suppress seizures but do not correct the
underlying brain abnormalities actually causing epilepsy. In
addition to that, epilepsy is often related to mood/anxiety disorder
and cognitive impairment [4,5]. Thus, there is a great need for new
‘‘antiepileptogenic therapies’’, also effective on behavior. To
develop such treatments, a better understanding of the underlying
mechanism of action of new substances is needed. During the
development of new therapies, the ‘Assay developments’ and ‘Lead
generation’ are necessary steps occurring before clinical testing.
Both these processes involve animal models-based test systems to
identify the effects of therapeutic agents. However, the search for
new treatments for seizures, epilepsies and their comorbidities
faces considerable challenges. This is due in part to gaps in our
understanding of the etiology and pathophysiology of most forms
of epilepsy. An additional challenge is the difﬁculty in predicting
the efﬁcacy, tolerability and impact of potential new treatments
on epilepsies and comorbidities in humans, using the available
resources. In fact, in 2012, out of 30,000 compounds screened byserved.
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Institute of Neurological Disorders and Stroke (NINDS), only 9 have
acquired an indication for seizures treatment [6].
Herein, we focus our attention on the advantages of using a
combination of time-locked video and EEG recording (usually
referred as video-EEG monitoring) and different behavioral tests
when studying chronic effects of antiepileptic drugs. In particular,
we take as a relevant example the case of rapamycin in the
treatment of epilepsy in tuberous sclerosis complex (TSC), a rare
multi-system genetic disease resulting in a combination of
symptoms including seizures [7].
2. From neural activity to behavior and back
The brain can be considered as a dynamic network of
interacting elements connected each other and with the external
environment. The synchronous activation among different brain
areas is essential in determining appropriate behavior. During
seizures some of the network connections fail, possibly leading to a
paroxysmal outcome. In many cases, network failure affects also
the interictal period and it could be linked to behavioral disorders
[8,9].
Thus, to characterize neural functioning in epilepsy, it may be
necessary to examine the brain activation at different levels/times
rather than at the level of the single event (i.e. seizure).
2.1. Local ﬁeld potential (LFP)
Extracellular recording of the electrical signal from animals
brain results in a signal that can be roughly segregated by
frequency-band separation into a high-frequency part (above
200–500 Hz), mainly reﬂecting multiple-unit spiking activity
(MUA) and a lower part (below 200–500 Hz), the so-called ‘local
ﬁeld potential’ (LFP) [10]. While the MUA most likely represents
extracellular action potentials of all neurons around the electrode
within a sphere of about 140–300 mm radius [11,12] LFP is
primarily generated by transmembrane current passing through
cellular membranes/synapses in the proximity of the electrode,
ranging from several hundred micrometers to few millimeters,
according to the recording conditions [13–16] although the spatial
extent of neurons that generate LFP is still a matter of debate
[17]. In other words, LFPs reﬂect primarily a weighted average of
synchronized dendro-somatic components of the synaptic signals
of a neural population, around the electrode tips. In the last few
decades, the interest in LFP has grown up, thanks to both
technological improvements in electrodes availabilities (i.e.,
simultaneous recording of a large number of different sites) and
the insight that LFP may provide information about sensory or
cognitive processes, deriving from the integration of a certain
neuronal population that cannot be measured by studying spiking
[18,19].
Commonly, cortical or deep brain recording in animal models of
epilepsy are used as a diagnostic tool to detect seizure or other
electrical abnormalities (i.e. interictal spiking). However, LFP and
simultaneous video recording (namely video-EEG monitoring) and
simple LFP analysis could be of great help if coupled with
behavioral analysis, when studying the effect of chronic drug
treatments in preclinical animal models.
2.2. Video-EEG recording
The study of epilepsy in animal models has greatly taken
advantage of simultaneous video and EEG recording. In video-EEG
monitoring, a video camera captures the behaviors and move-
ments of a subject/animal concurrently with EEG trace recording,
allowing a precise correlation between a given event and the EEGtrace (see Figs. 2 and 3 in [20]. Reviewing simultaneous EEG and
video data can be also useful for conﬁrming that an observed
behavior is an epileptic seizure, instead of a different episode (e.g.
scratching, movement disorder). In addition to that, video-EEG
monitoring is helpful in seizure classiﬁcation (e.g. with or without
convulsion, absence or partial versus generalized) and to deter-
mine its temporal progression (e.g. Racine scale). During interictal
periods, the video recording is essential for assessing the animal
activity (e.g. rest, active behavior, running, grooming), to better
correlate it with EEG. Video monitoring during dark phase is made
possible by the use of special video camera or infrared highlighting.
Electrode implantation is carried out under general anesthesia,
using inhalation (isoﬂurane, or sevoﬂurane) or intravenous
(mixture of ketamine, xylazine, and acepromazine, or tiletamine
and zolazepam) anesthetics. Montages with 2–4 recording
electrodes are generally used to record EEG from mice or rats,
after drilling precise holes in the skull with a high-speed micro drill
in a stereotactic frame. Usually, four recording electrodes are used
for rats whereas only one set of bilateral recording electrodes may
be sufﬁcient to monitor EEG activity in mice, according to the
smaller head size. Epidural recording screw/wire electrodes are
placed symmetrically over central or parietal areas and additional
electrodes are positioned over frontal areas [21–27]. In some cases,
deep electrodes are used, in particular for hippocampal activity
recording. In this case, stainless steel or tungsten insulated wires
are used [22,28,29]. The reference and ground electrodes may be
placed over posterior (occipital, cerebellum) and frontal regions.
Electrodes are soldered to pins/multielectrode connectors, secured
to the skull with cranioplastic or dental cement. The connection to
the ampliﬁer is ensured by ﬂexible cables, with or without electric
swivels, the second allowing easier and stress-free movements of
the animal. More sophisticated wireless systems such as New-
Behavior (Zurich, Switzerland) [30] or Data Science International
(St. Paul, MN) [29] can be successfully adopted. For research
purposes it is possible to adapt commercial video-EEG monitoring
systems for clinical use, although using a minimal amount of
available electrodes. However, it is possible to develop custom
systems by assembling different components, connected to a
personal computer. In this case, the video camera and biomedical
ampliﬁers should be connected by an analog to digital converter to
the computer, running appropriate software for video-EEG
monitoring. For recording, individual customized cages are usually
adopted. A Plexiglas room with a wire mesh coating (i.e. copper)
used as a Faraday cage is usually a convenient and useful solution.
According to the design and to the aim of the study, video-EEG
monitoring can be performed continuously [23,29] or in a
staggered way, i.e. recording selected time-deﬁned EEG periods,
ranging from 1 to 48 h, daily or at ﬁxed time points, throughout the
entire duration of the experiment. Although a continuous 24/7
recording represents the gold standard, several economic and/or
practical issues have to be considered in the design of the study. A
continuous recording implies that the acquiring unit has to be full-
time dedicated to a single animal until the end of the experiment,
and that a huge amount of video data has to be stored, analyzed,
and managed. On the other hand, staggered recordings could lead
to false negatives, as missed seizures, or more generally to high
variability in seizure count up [6].
Seizures are the most important feature to be analyzed within
EEG recordings in animal models of epilepsy. Electrographic
seizures (Fig. 1A) are generally self-limited (having an unambigu-
ous start and end, standing out from the background activity)
epochs of repetitive spike discharges, often starting as low
amplitude high frequency activity (tonic phase) and evolving into
higher amplitude and slower frequency bursts (clonic phase),
lasting at least 10–15 s [22,23,28,31]. A period of voltage
suppression is often observed at the end of the seizure (postictal
Fig. 1. Video-EEG monitoring in a mouse model of epilepsy: (A) A seizure detected by EEG, recorded from two epidural-screw electrodes, over left (LH) and right (RH) parietal
areas, referred to a posterior electrode (cerebellar screw). (B) Background interictal activity characterized by bilateral synchronous sharp waves. (C) DSA relative to 4.5 h of
normal background video-EEG monitoring. Different behaving states may be observed and analyzed ofﬂine by video inspection associated with EEG traces: REM sleep phase,
characterized by a pseudo-sinusoidal activity at around 7.5 Hz (left) and immobility; NREM sleep phase, deﬁned by a slower EEG activity (center) and immobility, and awake
phase, where the EEG shows an activity mostly centered around 5–7 Hz frequencies (right) and active locomotion.
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behavioral correlates of electrographic seizures and to rule out
artifacts or other false-positives, mainly attributable to grooming.
In addition, in different studies it was found that nonconvulsive
electrographic seizures usually occur before ictal EEG events
correlated with behavioral seizures [32,33].
The voluminous amount of video-EEG data collected in case of
prolonged monitoring studies may require many hours of manual
review and analysis. Automated seizure detection algorithms
could help in decreasing the manual workload and may sometimes
be more reliable than visual analysis [34]. Different automated
seizure detection algorithms have been described, for both off-line
[35,36] and real-time applications [37].
EEG traces can also be scored according to other epilepsy related
features such as interictal spikes [23], repetitive spike trains, or long
runs of repetitive spikes [24,26]. Interictal spikes (Fig. 1B) are
deﬁned as fast (<200 ms) and sharp waves, with amplitude at least
twice the amplitude of the background activity [21]. The interictal
background activity can be scored using a four-grade scale [38]:
grade 1 (normal) – normal background theta rhythm with no
epileptiform spikes, grade 2 (mildly abnormal) – mostly normal
background with some epileptiform spikes, grade 3 (moderately
abnormal) – mostly abnormal background with frequent epilepti-
form spikes, grade 4 (severely abnormal) – burst–suppressionpattern. The average score for spike frequency (spikes/minute) and
background activity (grade 1–4) are the most commonly considered
parameters to describe the interictal activity.
In addition to qualitative analysis, quantitative analysis can be
performed on EEG data (quantitative EEG or qEEG). Spectral
analysis of interictal background activity can easily provide useful
information to assess drug efﬁcacy [27,39,40]. EEG power spectra
can be obtained using the periodogram method, consisting in the
average of Fast Fourier Transformed set of selected homogeneous
artifact-free EEG epochs, usually lasting 2 s and possibly tapered
with a Hanning window. Absolute band power values are easily
extracted from power spectra, as sum of power bins corresponding
to the frequencies included within the band of interest. The
normalization of individual absolute band powers to the total
absolute power results into relative values, permitting compar-
isons among different animals. Several spectral parameters can be
deduced from EEG power spectra, among them theta/delta ratio
and mean dominant frequency (MDF) are often utilized. Theta/
delta ratio is useful in sleep staging [41]; in general higher values of
the ratio correspond to the awake state, while lower values are
mostly observed during NREM sleep. MDF is deﬁned as the ‘‘center
of mass’’ of a frequency band, and therefore it is calculated as the
weighted mean of the frequencies within the band of interest, with
their magnitudes as the weights. MDF indicates the shift of the
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rather than lower (slowing) values, independently of the total
power of the band.
Time–frequency analysis can be useful to detect spectral
changes throughout long-lasting EEG monitoring periods
(Fig. 1C). A compressed representation of the power spectrum
(spectral array) can be obtained putting successive spectra on a
stack, so that changes in frequency distribution over time can be
readily apparent. Two types of spectral array displays are available
in commercial instruments: the compressed spectral arrays (CSA)
and the density spectral arrays (DSA). The CSA presents the array of
power versus frequency versus time data as a pseudo three
dimensional perspective plot, whereas the DSA presents the same
data as a grayscale-shaded or colored two dimensional contour
plot [20]. Although both convey the same information, the DSA is
more compact, whereas the CSA permits better resolution of the
power data.
2.3. EEG and behavior
As widely demonstrated in humans, even in rodents there is a
clear association between regional EEG activity and behavioral
states during both physiological and pathological conditions [42–
45]. Oscillations provide indices of ongoing neural processing
among neurons surrounding the recording site [46,47]. For
example, hippocampal theta (4–12 Hz) and gamma (30–120 Hz)
oscillations in the hippocampus and prefrontal cortex (PFC) have
been correlated with short-term memory processing in rats [47–
49], similar to humans [50,51]. On the contrary, pathological
disruption of the hippocampus results in altered oscillatory
activity, that can impair cognitive ability [47,52–55]. In epilepsy,
the relationship between seizures and psychiatric comorbidities is
suggested to be bidirectional [56]. According to that, the
multidisciplinary approach based on combining video-EEG moni-
toring analysis and behavioral tests seems to be the best choice to
characterize epilepsy-related brain dysfunction, especially when
seizures are not yet manifestly evident or during interictal periods.
In R6/2 mice it was observed that at the earliest (pre-symptomatic)
state of the disease, mice progressively lost their normal diurnal
variation in sleep/wake behavior and this was associated with
considerable alterations in their sleep EEG [57]. In El mice, a model
of multifactorial epilepsy in which seizures are expressed in
response to both genetic and environmental antecedent, a power
increase within the 1–4 Hz frequency band has been reported
during the tail suspension test, suggesting a role for this frequency
band in seizure predisposition/induction [58]. An increase in
oscillatory activity, within the 5–6 Hz frequency band, has been
observed in the knockout mouse for the beta3 subunit of the
GABAA receptor treated with diazepam in early life, a mouse model
exhibiting spontaneous epilepsy [59]. More recently, high-
frequency oscillations (HFOs, 80–500 Hz) have emerged as
markers of abnormal neural network activity in both patients
and animal models of epilepsy [60–63]. Whereas frequency
oscillations in the 100–200 Hz range are believed to represent
normal activity [64], several lines of evidence suggest that faster
frequency oscillations (200–600 Hz) are generated by action
potentials of synchronously bursting principal cells, representing
pathological recurrent population spikes [65–67]. However, the
relation between HFOs and epileptogenesis has not still been fully
elucidated [68].
3. mTOR abnormal activity in the CNS leads to epilepsy
Among the different antiepileptic treatments under investiga-
tion, the mammalian target of rapamycin (mTOR) pathway
represents a logical candidate, because mTOR regulates multiplecellular functions that may contribute to epileptogenesis, includ-
ing protein synthesis, cell growth and proliferation, and synaptic
plasticity [7]. The importance of the mTOR pathway in epilepto-
genesis is best illustrated by tuberous sclerosis complex (TSC), one
of the most common genetic causes of epilepsy. In mouse models
of TSC, mTOR inhibitors prevent the development of epilepsy and
underlying brain abnormalities associated with epileptogenesis
(Fig. 2). Here we introduce the relevance of video-EEG monitoring
associated with behavioral tests as a relevant tool to monitor the
effects of rapamycin in TSC mouse models.
3.1. mTOR signaling overview
mTOR is a serine/threonine kinase of the phosphoinositide 3-
kinase (PI3K) related kinases and its name is related to its role as
the ‘‘mammalian Target Of Rapamycin’’. Rapamycin is a macrolide
produced by Streptomyces hygroscopicus, discovered in the 18th
century on Easter Island, the island later named Rapa Nui by French
Polynesian immigrants. mTOR is the catalytic subunit of two
distinct complexes called mTORC1 and mTORC2, which are deﬁned
by the association of mTOR with unique accessory proteins.
mTORC1 is the best characterized of the two mTOR complexes.
An important step forward in understanding mTORC1 regulation
came from the discovery that the TSC1 (hamartin)/TSC2 (tuberin)
protein complex negatively controls its activity [69]. Various
physiological and pathological stimuli converge on this TSC1/TSC2
complex to regulate mTORC1 activity. mTORC1 responds to these
upstream signals by modulating multiple downstream pathways,
which mediate cellular growth, proliferation, metabolism and
survival. As opposed to growth factors and cytokines, many cellular
stresses as low energy, hypoxia, and DNA damage act, at least in
part, through TSC1/2 to inactivate mTORC1. Once activated, the net
effect of mTORC1 signaling is the phosphorylation of downstream
proteins that regulate cellular processes involved in protein
synthesis and other cellular functions. The best-characterized
effectors of mTORC1 are eIF4E binding protein (4E-BP1) and S6
kinase 1 (S6K1) [70].
As compared to mTORC1, little is known about mTORC2
pathway regulation and, in particular, about its upstream
activators. In general, mTORC2 promotes cell spreading and F-
actin polymerization [71]. In the CNS, mTORC2 controls actin
dynamics in neuronal dendritic spine morphology, thus possibly
having a role in TSC-related brain manifestation.
3.2. mTOR signaling in the central nervous system
Recent studies between mTOR and neurological disease have
demonstrated that mTOR have a signiﬁcant impact on the nervous
system. mTORC1 supports neuronal activity by regulating the
translation of speciﬁc mRNAs as well as regulation of neurotrans-
mitter receptor expression [72]. In fact, mTOR is required for both
(short term) activity-dependent local protein synthesis and (long
term) synaptic plasticity [73].
Given the multiple roles of mTOR in the CNS, it is reasonable to
think that mTOR pathway could be involved also in epileptogen-
esis. Particularly, abnormal cell growth due to mTOR activation
could affect the excitability of neuronal circuits and promote
seizures. In fact, mutations in TSC genes can induce profound
alterations in network properties and the imbalance between
excitation and inhibition can lead to epilepsy, mental retardation
and autism. Finally, mTOR is also a pivotal regulator of the
homeostasis of several distinct stem cell pools in which it ﬁnely
tunes the balance between stem cell self-renewal and differentia-
tion. mTOR hyperactivation in neural stem cells (NSCs) has been
etiologically linked to the development of TSC-associated neuro-
logical lesions, such as brain hamartomas and benign tumors
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the derangement of their homeostasis, thus leading to tuberous
sclerosis complex development.
3.3. ‘‘mTORpathies’’ in the central nervous system
Among the geneticcauses of epilepsy, tuberous sclerosis complex
(TSC) has provided the strongest link between mTOR and epilepsy.
TSC is a common inherited tumor predisposition syndrome,
affecting approximately 1 in 7500 individuals [74]. TSC results
from mutations of either TSC1 gene or TSC2 gene [76]. Individuals
with TSC develop benign tumors in multiple organs, including the
retina, skin, lung, kidney, and brain. The pathognomonic lesion of
TSC is the cortical tuber, a benign growth of immature neuroglial
cells in the brain that forms early in development and contain
dysmorphic neurons, excessive number of astrocytes and giant cells
[77]. The number and location of these tubers correlates with the
neurologic complications associated with the disease, including
epilepsy, autism, and mental retardation [78]. However, some
patients continue to seize after tuberectomy [79].
Individuals with TSC are also predisposed to the development of
dysplastic growths called subependymal nodules that arise from
cells lining the lateral ventricle [31,75]. While often asymptomatic,
subependymal nodules may progress to form subependymal giant
cell astrocytomas (SEGAs).
Abnormalities in mTOR signaling that are central to TSC may
also be important for epilepsy in other pathologically related
tumor syndrome or malformation of cortical development. For
instance, patients with PTEN mutations have macrocephaly,
mental retardation, epilepsy, hamartoma syndrome. Since PTEN
is an inhibitor of mTOR, PTEN knockout mice share neurological
features that closely resemble the TSC mouse models [80]. Al-
though single gene mutations are rare cause of epilepsy, these
genetic disease involving TSC and PTEN mutations demonstrate
‘‘proof of principle’’ that mTOR inhibition may represent an
attractive antiepileptogenic strategy and allows the use of the term
‘‘mTORopathies’’ to describe mTOR signaling abnormalities leading
to epilepsy and cortical malformations (Fig. 2).Fig. 2. mTOR and rapamycin: mTOR complexes (mTORC1 and mTORC2) are central signa
mTOR signaling pathway may be abnormally activated by a variety of genetic defects or a
or traumatic brain injury. As a consequence, mTOR hyperactivation causes multiple do
channels expression, apoptosis, autophagy, axonal sprouting and neurogenesis. Inhibiti
preventing epileptogenesis in such a setting.Besides genetic driven epilepsy, mTOR signaling represent a
logical mechanism for triggering epileptogenesis in acquired
epilepsies. Acquired epilepsy is characterized by an initial insult
such as trauma, stroke, or an episode of status epilepticus (SE) that
causes subsequent recurrent seizures. The time between the insult
and the ﬁrst seizure is normally referred as the latent period. This
latent period is characterized by numerous molecular and cellular
abnormalities that could, at least in part, utilize mTOR dependent
pathways.
In light of these considerations, experimental evidences for the
involvement of mTOR pathway in epileptogenesis and the
rationale therapeutic effects of rapamycin have been obtained
by different animal models of acquired epilepsy [81]. In the kainate
model of acquired epilepsy, a single injection of kainate causes an
initial episode of SE, followed by a latent period during which
different cellular and molecular mechanisms may contribute to
epileptogenesis, as changes in ion channel expression, neuronal
death, neurogenesis, synaptic reorganization, axonal sprouting
[82]. After this latent period, the animal develops seizures. mTOR is
abnormally activated by kainate status epilepticus [22] and in the
related pilocarpine model [83]. In the kainate model, there are two
phases of transient mTOR activation, an acute phase lasting several
hours that occurred during the SE and, after a couple of days, a
second longer phase lasting several weeks. Rapamycin adminis-
tered before SE was able to block both phases of mTOR activation
and reduce seizures and consequent neuronal death, mossy ﬁber
sprouting and neurogenesis [22]. Similarly in the in the pilocarpine
model, rapamycin can prevent seizures frequency and mossy ﬁber
sprouting [83,84].
The effect of rapamycin in SE-induced models appears to be due
to antiepileptogenic and not simply to a seizure-suppressing
action. In terms of mechanisms, mossy ﬁber sprouting, neuronal
death, and neurogenesis have all been implied in mediating
epileptogenesis and rapamycin may, at least partially, account for
the anti-epileptogenic effects [82]. Inhibition of mTOR may also
reduce apoptotic pathways potentially contributing to neuropro-
tective effects, thus protecting the neurons in remaining functional
in the face of rising levels of stress in seizures [22,85].ling hubs for coordinating multiple mechanisms responsible of epileptogenesis. The
cquired injuries, including upstream TSC or PTEN gene mutations, status epilepticus,
wnstream mechanisms causing epileptogenesis through aberrant regulation of ion
on of mTOR by rapamycin may represent an attractive and effective treatment for
M. Cambiaghi et al. / Seizure 27 (2015) 30–39 353.4. Animal models of mTOR signaling abnormalities
Among the genetic causes of epilepsy, TSC remains the prime
example of mTOR dysregulation in epileptogenesis. To reproduce
temporally and spatially the development of the neurological
alterations typical of tuberous sclerosis complex, different CNS-
restricted conditional knockout murine models have been gener-
ated, by causing loss of either Tsc1 or Tsc2 in differentiating or
differentiated neuronal cells (Tsc1c/c/Syn-Cre+ and Tsc1c/c/CaM-
KII-Cre+ mice) [86,87] or in differentiated astrocytes [Tsc1c/c/
hGFAP2.2 kb (also known as Tsc1c/c/hGFAP1-Cre+) and Tsc2c/c/
hGFAP2.2 kb (also known as Tsc2c/c/hGFAP1-Cre+) mice]
[88,89]. Notably, most of these animal models caused by Tsc1 or
Tsc2 loss show epileptic seizures and neurological abnormalities
(Table 1). Given that CTs, SENs and SEGAs are believed to originate
from a neural stem cell (NSC) undergoing abnormal differentiation,
NSC-targeted mouse models of TSC have also been recently
produced by deleting: (1) Tsc2 in embryonic radial glial cells
(RGCs) (Tsc2c//hGFAP2-Cre+ mice) at embryonic day 13.5 (E13.5)
[90] (2) Tsc1 in Emx1-expressing embryonic dorsal telencephalic
neuroepithelial progenitors (NEPs) at E9.5 [31,91], (3) Tsc1 in
embryonic radial glial cells (RGCs) (Tsc2c//hGFAP2-Cre+ mice) at
embryonic day 13.5 (E13.5) [75], (4) Tsc1 in embryonic E16.5
progenitors [92] and(5) Tsc1 in postnatal SVZ NSCs [93,94]. Deletion
of Tsc1 or Tsc2 at different developmental stages results in a gradient
of phenotypes, with the most severe phenotypes being associated
with mutations in early embryonic neural progenitors [74]. As such,
these same CNS restricted TSC mouse models could be exploited to
highlight potential genotype-phenotype correlations in TSC.
Among the different models, Tsc2c//hGFAP2-Cre [90], in which
Tsc2 mutation occurs in RGCs, recapitulates many aspects of the
disease including epilepsy, macrocephaly, cytomegaly, lamination
defects and astrogliosis, features that were only partially shown in
models induced by mutations in differentiated neuronal and
astroglial cells [86–89]. These mice show increased numbers of
intermediate progenitors at the expense of post-mitotic neurons,
showing that derangement of the homeostasis of neural progenitors
due to mTOR activation leads to TSC-associated lesions. However,
post-natal SVZ alterations were not documented in this model.
To improve the pathological signiﬁcance of cell targeting a
novel model was generated by deleting Tsc1 in NEPs [31,91] by
using the Emx1Cre donor mice. The Emx1-expressing domain gives
rise to both the cerebral cortex and the post-natal SVZ [74], which
are the two brains regions where tubers and SEN/SEGAs arise.
Particularly, Tsc1c/ Emx1-Cre mutant mice recapitulated many
aspects of the human disease, including spontaneous epilepsy,
cortical lamination defects, hydrocephalus, cytomegaly, macro-
cephaly, hypomyelination, glia pathology, and, most relevantly,
postnatal SVZ abnormalities, which reminded of TSC-associated
SENs [31]. Consistent with the role of mTOR in other stem cell
compartments, mTOR hyperactivation in NSCs caused enhanced
generation of neural stem/progenitors, followed by prematureTable 1
Phenotypic characterization of most widely used CNS-restricted animal models of mTO
Reference Model C
Uhlmann, 2002, Ann Neurol [88] Tsc1c/ 2.2Kb hGFAP cre A
Zeng, 2011, Hum Mol Genet [89] Tsc1c/c 2.2Kb hGFAP cre A
Meikle, 2007, J Neurosci [86] Tsc1c/ Syn cre N
Way, 2009, Hum Mol Genet [90] Tsc2c/ hGFAP cre R
Magri, 2011, Cell Stem Cell [31] Tsc1c/ Emx1Cre mice N
Magri, 2013, DM&M [75] Tsc1c//hGFAP2-Cre+ mutant mice R
Goto, 2011, PNAS [100] Tsc1c/ NesTA+ TetO–Cre+ mutant mice R
Ljungberg, 2009, DM&M [24] Ptenc/c Gfap-Cre A
Zhou, 2009, J Neurosci [101] Ptenc/c NS-Cre Nneuronal differentiation and impaired maturation, both during
embryonic and postnatal development. Overall, these ﬁndings
indicate that mTOR is a critical regulator of NSC self-renewal and
differentiation of embryonic NEPs/NSCs.
Of note in this model, the functional maturation of the
excessively generated mutant neuronal cells was defective, leading
to the generation of aberrant neurons and to the development of
spontaneous seizures.
3.5. Rapamycin treatment in mouse models of mTOR-dysregulated
diseases
The efﬁcacy of mTOR inhibitors in treating epilepsy and
neurological lesions associated to TSC has been assessed in several
mouse models. Rapamycin treatment reduced the severity of
epilepsy, increasedsurvival, reduced cortical cytomegaly andgliosis,
improved myelination, increased survival, and restored mTORC1
signaling in several mouse models of TSC [31,75,80,87,95,96]. The
effect of blocking the abnormal mTOR activation in the development
of epilepsy has been particularly analyzed in knockout mice
involving inactivation of the Tsc1 gene primarily in glial ﬁbrillary
acidic protein (GFAP)-positive cells. These mice develop seizures at
4 weeks of age [21]. Early rapamycin treatment started prior to the
onset of seizures prevents epilepsy, whereas late treatment reduced
seizure frequency in mice that already have epilepsy [96].
However, despite these encouraging results, all these studies
clearly indicated the reversibility of rapamycin activity, given that
the conditions of mutant mice worsened after rapamycin
discontinuation, including the histopathologic abnormalities and
epilepsy, leading to death [96]. A study about mTOR inhibition
treatment expanded our knowledge. Three different rapamycin
treatment regimens – prenatal, postnatal, and pre/postnatal
(combined) – were compared in a mouse model of TSC
[97]. Combined regimen was the most effective in rescuing brain
abnormalities, but surprisingly, it was not beneﬁcial as postnatal
regimen in rescuing learning and memory function of mutant
animals. Despite the reversibility of rapamycin, its reported effects
are of potentially high signiﬁcance since they appear to be
antiepileptogenic and not simply seizures-suppressing. Indeed, in
contrast to standard seizure treatments, rapamycin has no a direct
effect on neuronal excitability [98] but instead it interrupts
gradually the neuropathologic and cellular processes mediating
epileptogenesis in these models [95,96].
4. EEG recording in rodents models of epilepsy chronically or
sub-chronically treated with rapamycin
Since rapamycin was ﬁrstly used for the treatment of epilepsy
[96], several chronic or sub-chronic studies have been conducted
to test its potential efﬁcacy in different rodent models. However,
only few of them went deep into the characterization of both
neurophysiological and behavioral analysis. In Table 2, weRopathies showing spontaneous seizures.
ell type targeted Cortical
abnormalities
Cellular
abnormalities
Lifespan
(days)
strocytes No ND 50
strocytes No ND 50
eurons No Yes 35
adial Glia Cells Yes Yes 21
eural Epithelial Progenitors Yes Yes 18
adial Glia Cells Yes Yes 21
adial Glia Cells No Yes 21–28
strocytes Yes Yes 70
eurons No Yes Normal
Table 2
EEG outcomes in animal models of epilepsy sub-/chronically treated with rapamycin.
1st Author year,
journal
Animal model Rapamycin treatment Neurophysiological and
behavioral analysis
Notes
Zeng, 2008, Ann.
Neurol [96]
Tsc1GFAPCKO mice 3 mg/kg i.p. From 6 weeks
(5 days/w)
Video-EEG monitoring 48 h
continuous once a week
(epidural screws parietal)/
seizures, interictal spike freq,
interictal EEG grade (scale of 1–
4)
1st paper to use rapamycin in
epilepsy. Decreased number of
seizures (model characterized
in Erbayat-Altay,
2007 Epilepsia)
Zeng, 2009,
J Neurosci [22]
Acute kainite induced seizures
in rat
6 mg/kg i.p. 24 h after SE daily
for 6 days; then every other day
for 5 weeks
Video-EEG monitoring
(hippocampus/epidural screws
frontoparietal and parietal)/
Racine scale
Phenobarbital (30 mg/kg/d i.p.
for 6 days) as a control.
Rapamycin postponed the
onset and decreased the
number of seizures.
Ljungberg, 2009,
DM&M [24]
NS-Pten mice (cortical
dysplasia)
10 mg/kg i.p. From 4 to 5 weeks
(5 days/w)
Video-EEG monitoring 2–4 h
twice/week from 4 w to 9 w
(depidural screws parietal)/
seizure quantiﬁcation
Rapamycin treatment reduces
the severity of electrographic
abnormalities. This
antiepileptic effect appears to
be long lasting, persisting for at
least 3w after cessation of the
treatment.
Zhou, 2009,
J Neurosci [101]
Nse-cre; PtenloxP/loxP
(macroceph. autism)
10 mg/kg i.p. From 10–12
weeks for 4–6 weeks (5 days/w)
EEG/EMG (epidural frontal and
occipital) from 10 to 12 w for
5 w, 3days/w/OFT and social
interaction test
Decreased seizures frequency
and duration from 2 w after
rapamycin onset. Increased
time in the center in the OFT.
Increased social interaction
(also in presymptomatic group)
Buckmaster, 2011,
J Neurosci [28]
Pilocarpine-induced mouse 1.5 or 3 mg/kg i.p. From 24 h
after pilocarpine, daily for
2 months
Video-EEG monitoring 9 h/daily
for 1 mo, 2 mo after pilocarpine
(right, dorsal hippocampus)/
Racine scale
Seizure frequency was similar
in vehicle- and rapamycin-
treated mice that had
experienced status epilepticus.
Behavioral seizure severity was
similar in vehicle- and 3 mg/kg
rapamycin-treated mice
Sunnen, 2011,
Epilepsia [26]
NS-Pten mice (cortical
dysplasia)
10 mg/kg i.p. (a) w 4–5; (b) w
4–5/10–11/16–17 (5 days/w)
Video-EEG monitoring 4 h at 4,
6 and 9 w (hippocampus/
epidural screws parietal)/
seizure quantiﬁcation
(a) Decreased epileptiform
activity till w10; (b) decreased
epileptiform activity till w18
(end of the study); decreased
mortality.
Goto, 2011,
PNAS [100]
Tsc1cc Nestin-rtTA+ TetOp-cre+/
TSC model mice
PND 8–20 1 mg/kg PND 21 to
P40 3 mg/kg i.p. (3 days/w)
Video-EEG monitoring
(epidural screw, parietal)
PND25 to PND58, over several
weeks (16 to 41 h recordings)/
seizure quantiﬁcation
Increased lifespan
(neurological symptoms and
death within 2w of wash out).
Seizure suppression
Raffo, 2011,
Neurobiol Dis [102]
Rat model of infantile spasm
(doxorubicin and LPS)
3 mg/kg i.p (a) PND 4–12, 1 mg/
kg (b) PND 4–12, 3 mg/kg (c)
PND 4 6 mg/kg, P5-6
Video-EEG monitoring
(epidural screw, parietal) from
PND7/seizure quantiﬁcation/
reﬂexes test/Barnes maze
Daily 6 mg/kg resulted in 100%
mortality by P12 (n = 4); dose-
related reduction in spasms but
no effects on other seizures or
interictal abnormalities.
Rapamycin improved Barnes
maze in Wt.
Sliwa, 2012,
Neurosci Lett [103]
Electrical stimulation of the
amygdala in rat
6 mg/kg i.p. From 24 h after SE
daily for 2 weeks
Video-EEG monitoring 2d-on-
2d off (epidural screw, frontal
dx and amygdala)
No effects on animals
developing epilepsy, latency of
the ﬁrst seizure and frequency.
van Vliet, 2012,
Epilepsia [104]
Electrical stimulation of the
angular bundle in rat
6 mg/kg i.p. Daily for 7 days
after SE; every other day for
5 subsequent weeks
Video-EEG monitoring 24 h/day
Seizure scoring/Racine scale
Rapamycin-treated rats
developed hardly (9/12) or no
(3/12) seizures during the 6-
week treatment
Brewster, 2013,
PLOS ONE [105]
Pilocarpine-induced rat 6 mg/kg i.p. From 2 weeks after
SE every other day for
4 treatments
Video-EEG monitoring
(hippocampus/epidural screws
parietal)/seizure
quantiﬁcation/MWM/NOR/
Social interaction test
Rapamycin improved memory
acquisition in SE rats (no effects
on sham).
No effects on interictal spike
frequency following SE.
Magri, 2013,
DM&M [75]
Tsc1c//hGFAP2-Cre+ mice 6 mg/kg i.p. From P8 to P40
every other day
Video-EEG monitoring from
PND12 (depidural screws
parietal)/seizure quantiﬁcation
All mutant mice treated by this
regimen stopped developing
seizures and were still alive at
P40. 10 days after wash out all
mutant mice developed
seizures
Cambiaghi, 2013,
Neuropharm [27]
Tsc1c/ Emx1Cre mice 6 mg/kg i.p. From P8 to P40
every other day
Video EEG monitoring at
PND40 (duration 1–2 h).
2 screw parietal electrodes,
reference occipital/visual
inspection, power spectra, DSA-
MDF/behavioral tests: EPM,
TST, OFT, FST
Rapamycin-treated mutant
mice displayed a reduction in
anxiety- and depression-like
phenotype, as shown by the
EPM/OFT and FST, respectively.
These results were inline with
EEG power spectra (MDF in the
theta-alpha band)
M. Cambiaghi et al. / Seizure 27 (2015) 30–3936
Table 2 (Continued )
1st Author year,
journal
Animal model Rapamycin treatment Neurophysiological and
behavioral analysis
Notes
Abs, 2013, Ann
Neurol [30]
Tsc1f/2::Cag-CreERT1 mice 5–10 mg/kg i.p. At days 1-2-3-
4-6-8-10 after seizure onset
Video-EEG monitoring with
wireless recording Duration
16 h/Seizures scoring; mean
seizure frequency/Interictal
spike analysis
Rapamycin treatment fully
abolished the seizures
List of abbreviations: EMG, electromyography; EPM, elevated-plus maze; FST, forced-swim test; MWM, Morris water maze; NOR, novel object recognition; OFT, open ﬁeld test;
PND, post-natal day; TST, tail suspension test.
M. Cambiaghi et al. / Seizure 27 (2015) 30–39 37summarized the literature published so far (PubMed 07/2014),
according to the following criteria, (i) use of EEG and (ii) chronic/
sub-chronic rapamycin treatment in (iii) rodent model of
epilepsy). We noticed that EEG or video-EEG monitorings are
often limited only to seizure count/duration analysis. In some
other cases the video recording is also adopted for better deﬁning
Racine scale analysis. In the TSC1-Emx1Cre mice model we
analyzed whether chronic rapamycin administration was also
associated with changes in behavioral and background EEG
features [27]. In this model we observed that rapamycin had a
clear effect on reducing depressive-like behavior, also observed in
treated wild-type mice but not in heterozygous animals. Similar
outcomes were found in an anxiety-like test, although the
observed results might be affected by multiple variables, and
not exclusively by anxiety. In addition to that, in wild-type animals
treated with chronic rapamycin we found a slight but signiﬁcant
decrease in theta-alpha MDF, together with behavioral changes,
suggesting a possible mild brain dysfunction associated with drug
treatment. Finally, a signiﬁcant inverse correlation has been found
between theta-alpha MDF and the ratio between open arm/total
arm entries of the elevated-plus maze (EPM) anxiety-like test.
Together these results suggest that both Tsc1 deletion and chronic
rapamycin treatment might have a role in modulating behavioral
and brain activity, and point out to the potential usefulness of
background EEG analysis in tracking brain dysfunction in parallel
with behavioral testing.
However, to our knowledge, we found no evidence for a deeper
analysis of the in vivo electrical activity during periods free of
seizures in animals treated with rapamycin in other studies. In few
of these studies EEG recording and behavioral were conducted,
such as depression- or anxiety-like tests (e.g. Forced swimming,
Open-ﬁeld or Sucrose intake), memory (e.g. Novel object
recognitio, Morris Water Maze) or social behavior (e.g. Social
interaction) tests.
4.1. Local versus surface: clashing or complementary recordings?
Although epidural electrodes are the standard for seizure
recording, a more detailed analysis in order to detect the origin and
the temporal progression of ictal events should be performed by
using intracranial or high-density, multi electrode recordings.
According to Table 2, only a minority of studies used deep
electrodes in hippocampus, although different areas might be of
great interest (e.g. thalamus or deep cortical regions). While scalp
(or cortical) recordings might be the best choice in order to detect
more global brain effects during chronic treatments (generalized
seizures and/or gross alterations), local recordings (e.g. deep
electrodes) are essential for spatio-temporal synchronization of
distinct brain areas, in particular during inter-ictal periods at
various times during chronic therapy. Indeed, different brain areas
are usually involved in epilepsy [99] and the possibility to record
simultaneously from different areas allows coherence and cross-
correlation analysis [47,50,64] for determining the exact cross-talk
between them during seizures but, more importantly, in inter-ictal
periods and/or during speciﬁc behaviors.5. Conclusions and future direction
Even though EEG monitoring is a technique dating back to
nearly one century ago, the possibility to use it in a multidisci-
plinary approach makes it more attractive for the study of epilepsy.
A deeper analysis of LFP recording in animal model of epilepsy
chronically treated with antiepileptic drugs (such as rapamycin)
should be considered a gold standard in preclinical studies,
especially when adopting genetic animal models, for both seizure
characterization, background EEG abnormalities and correlation
with behavior. Overall outcomes clearly indicate that rapamycin is
an ideal drug for chronic tests in animal models of TSC but also in
different rodent model of epilepsy. However, results are mixed and
some studies reported that rapamycin treatment was not able to
ameliorate epilepsy (i.e. seizure frequency). On one hand, these
results suggest that a deeper knowledge of rapamycin mechanisms
of action in epilepsy is needed. On the other hand, according to the
large quantity of positive results, whether not evident in the
number/latency of seizure are observed the effect of rapamycin
should be tested by background EEG analysis and/or by different
behavioral tests, according to the animal model being examined. In
addition to that, it would be necessary to develop standard
protocols for the analysis of chronic drug treatment in animal
models of epilepsy. With regard to chronic rapamycin administra-
tion one of the main goals will be to determine well deﬁned time
windows and dosage for acute, sub-acute and chronic treatments.
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